Hyundai Bioscience

현대바이오 · 048410

Materials Chemicals · KOSDAQ

Small-cap

Market cap US$791.6M (₩1.1T)

Overview

Hyundai Bioscience develops and supplies bioscience-related materials and compounds, with its research and development activities forming a central part of its operations.

It is listed on KOSDAQ, South Korea's technology and small-cap stock exchange. The filing indicates that research and development activity is a prominent component of the business, suggesting the company is at an active development stage for its product pipeline.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$2.5M

▼ −76.6% YoY

Operating profit · FY2025

−US$13.2M

Turned to loss

Net income · FY2025

−US$16M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$6.9M(₩9.5B)	US$10.9M(₩15.1B)	US$2.5M(₩3.5B)
Operating profit	−US$7.1M(−₩9.8B)	US$573.2K(₩791M)	−US$13.2M(−₩18.2B)
Net income	−US$10.5M(−₩14.5B)	−US$5M(−₩6.9B)	−US$16M(−₩22.1B)

Revenue

FY2023US$6.9M
FY2024US$10.9M
FY2025US$2.5M

Operating profit

FY2023−US$7.1M
FY2024US$573.2K
FY2025−US$13.2M

Net income

FY2023−US$10.5M
FY2024−US$5M
FY2025−US$16M

Key ratios (FY2025)

ROE

-20.0%

Debt/Eq

18.1%

Op. margin

-516.3%

Net margin

-629.1%

Rev. YoY

▼ −76.6%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?